About CKLF-like MARVEL transmembrane domain-containing protein 3
CKLF-like MARVEL transmembrane domain-containing protein 3 (CMTM3) is a protein
from Homo sapiens identified by UniProt accession
Q96MX0, 182 residues long.
MolForge cross-references it against 0 known binders and
80 disease associations.
Target properties
| Protein name | CKLF-like MARVEL transmembrane domain-containing protein 3 |
|---|
| UniProt accession | Q96MX0 |
|---|
| Gene | CMTM3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 182 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (80)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.11
- neoplasm · score 0.10
- high density lipoprotein cholesterol measurement · score 0.09
- sex hormone-binding globulin measurement · score 0.09
- aspartate aminotransferase measurement · score 0.09
- serum alanine aminotransferase measurement · score 0.09
- low density lipoprotein triglyceride measurement · score 0.09
- hepatocellular carcinoma · score 0.08
- esophageal squamous cell carcinoma · score 0.08
- Chordoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96MX0-F1 | alphafold | PREDICTED | 79.72 | — |
Amino-acid sequence (182 residues)
MWPPDPDPDP DPEPAGGSRP GPAVPGLRAL LPARAFLCSL KGRLLLAESG LSFITFICYV ASSASAFLTA PLLEFLLALY FLFADAMQLN DKWQGLCWPM MDFLRCVTAA LIYFAISITA IAKYSDGASK AAGVFGFFAT IVFATDFYLI FNDVAKFLKQ GDSADETTAH KTEEENSDSD SD
Explore CKLF-like MARVEL transmembrane domain-containing protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets